Relative Bioavailability of Phase II and Phase III formulations of AZD0530
Study identifier:D8180C00033
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Phase I, Randomised, Open-label, Cross-over, Single Centre Study in Healthy Volunteers to determine the Relative Bioavailability of the Phase III tablet formulation to the Phase II tablet formulation of AZD0530
Medical condition
Healthy
Phase
Phase 1
Healthy volunteers
Yes
Study drug
AZD0530
Sex
All
Actual Enrollment
18
Study type
Interventional
Age
18 Years - 45 Years
Date
Study Start Date: 01 Nov 2008
Primary Completion Date: -
Study Completion Date: 01 Mar 2009
Study design
Allocation: Randomized
Endpoint Classification: Bio-availability Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Basic Science
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 | Drug: AZD0530 of both the Phase II and Phase III AZD0530 125mg tablet variants (A and B) in a random order. Drug: AZD0530 Part II: Single doses of AZD0530 125mg oral solution and 2 out of 4 125mg tablet variants (C, D, E and F) in a random order. |
Contacts
Investigators
Principal Investigator
Raj Chetty
AstraZeneca, Clinical Pharmacology Unit, Alderley Park
